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A B S T R A C T
Background: Chronic antiepileptic drug use is associated with bone loss. We sought to assess the
longitudinal effect of antiepileptic drug on serum 25-hydroxyvitamin D [25(OH)D] levels and bone
mineral metabolism markers.
Methods: Patients in the emergency services or those in neurology outpatient department with history
of seizure were characterized and included in the study prospectively. Daily dietary intake of calories,
calcium, phosphorus and phytates were characterized by dietary recall method. Base line bone mineral
parameters – serum calcium, phosphorus, alkaline phosphatase (SAP), tartrate resistant acid
phosphatase (TRACP), 25(OH)D levels, parathyroid hormone (PTH) and urinary calcium creatinine
ratio (Ca.Cr), urinary calcium/kg/bodyweight (BW) and phosphate excretion index (PEI) were
determined. Patients on AED therapy with normal 25(OH)D levels were followed up and were re-
evaluated at the end of 6 months.
Results: The daily dietary calcium intake of the subjects was lower than the RDA (Recommended Dietary
Allowance) by ICMR (Indian Council of Medical Research). The diet was high in phytates. Two-thirds of
the recruited subjects were vitamin D deﬁcient. Subjects with normal 25(OH)D levels at base line
showed a signiﬁcant fall of 25(OH)D levels, urinary calcium, urinary calcium/kg/BW and TRACP levels at
the end of 6 months irrespective of the AED used or the plasma level of AED.
Conclusions: Hypovitaminosis D is common in our population. Subjects with normal 25(OH)D levels,
irrespective of the type of antiepileptic medications even at sub-therapeutic serum levels of the drug,
went into 25(OH)D deﬁciency and insufﬁciency states. Theoretically it can be worthwhile to supplement
calcium and vitamin D even before initiation of antiepileptic therapy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a common neurological disorder affecting all age
groups. It is one of the world’s most prevalent non-communicable
diseases.1 In India, 90% of the estimated 5.5 million people with
epilepsy are from rural population and three-fourths of themmaybe
deprivedof speciﬁc treatmentasper thepresent standard.Newcases
are close tohalf amillioneachyearand the incidence rates far exceed
prevalence ﬁgures.1 In India, treatment gap is gradually getting
narrowed as community based approaches are offering effective
treatment strategies.2,3 A number of medications are currently used
in the treatment of epilepsy. The older AED’s are Phenobarbital (PB),
Phenytoin (PHT), Carbamazepine (CBZ), Primidone (PRM), Sodium* Corresponding author. Tel.: +91 09731561819.
E-mail addresses: bneuro_5@rediffmail.com (B. Menon),
cvhari5endo@rediffmail.com (C.V. Harinarayan).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.01.006valproate (VPA)andClonazepam(CZP).NewerAED’sareLamotrigine
(LTG), Topiramate (TPM), Clobazam (CLB), Oxcarbazepine (OXC) and
Levetericitam (LEV). Use of AED’s has acute and chronic side effects.
Chronic use of AED can affect bone health. Maintenance of bone
health and bone density is a dynamic process. Reports of AED
induced biochemical abnormalities suggestive of osteomalacia have
been reported in the early 70s.4–7 Recent studies have also shown
that chronic use of AED has an adverse effect on bone mineral
metabolism8,9 and bone mineral density.8,10
There are no set guidelines whether to supplement calcium and
vitamin D in a patient with epilepsy from day of initiation of AED
therapy or whether a base line data of markers of bone formation,
resorption and vitamin D levels are mandatory. Moreover, studies
so far have been cross sectional studies or longitudinal studieswith
patients already on AED therapy.We therefore sought to assess the
longitudinal effects of antiepileptic drug on serum 25-hydro-
xyvitamin D [25(OH)D] levels and parameters of bone mineral
metabolism before and after AED therapy.vier Ltd. All rights reserved.
B. Menon, C.V. Harinarayan / Seizure 19 (2010) 153–1581542. Methods
All subjects in the emergency services or the neurology
outpatient department of a tertiary referral center with history of
seizure and not on treatment were included in the study
prospectively. After stabilization, a comprehensive proforma which
included the semiology of seizure, family history of seizures, febrile
seizures and general medical history was taken. Routine biochemi-
cal investigations including hemogram, renal function tests, liver
function tests and serum electrolytes was done in all subjects.
Electroencephalography (EEG) was done in all subjects. Neuroim-
aging with either Computerized tomography scan or Magnetic
resonance imaging of the brain was done in selected subjects as per
the patient’s semiology. The epileptic seizure and epileptic
syndrome was classiﬁed according to the International League
Against Epilepsy (ILAE) classiﬁcation of epileptic seizures and
epileptic syndromes. Subjects newly initiated onAEDwere included
in thestudy. SubjectswhowerealreadyonAED,ondrug therapythat
interfere with vitamin D metabolism, those with hepatic, renal,
dermatological disorders, chronic smokers and alcoholics, pregnant
women, mentally challenged and institutionalized patients were
excluded from the study. This study was supported by a grant from
Indian Council of Medical Research (ICMR), New Delhi.
The study center is located 13.48N latitude. The geography of all
living residence of patients were around this latitude. The average
duration of sunlight is around 8–10 h per day throughout the year.
Winter is short with lowest temperatures ranging from 17 to 30 8C
with scanty rainfall with cloud free sunshine of 8–10 h a day. Most
often, there is little seasonal variation of the peak intensity of
sunlight.11 The UV index of the region is 6–10 throughout the
year.11
The dietary assessment of total energy, calcium, phosphorous
and phytates were documented by recalling the diet consumed in
the previous 5–7 days. The documentation of dietary pattern was
by a single observer. The validity and repeatability of documenta-
tion was rechecked at random by one of us (authors) over the
period of the study. There was no signiﬁcant error in documenta-
tion of diet history. From the raw weights; the total energy,
calcium, phosphorous and phytate intakes were calculated using a
published food composition table, detailing the nutritive value of
Indian foods.12
For all subjects, peripheral venous blood samples were
collected in the fasting state at 8 am in the morning without
applying tourniquet for the estimation of serum calcium,
phosphorus, alkaline phosphatase (SAP), creatinine, albumin and
serum tartrate resistant acid phosphatase (TRACP). Samples were
collected on ice for 25(OH)D and N-tact parathyroid hormone
(PTH). The serumwas separated in a refrigerated centrifuge at 4 8C
and stored at 20 8C until the analysis for the estimation of
25(OH)D and PTH.
Serum calcium, phosphorus, alkaline phosphatase, creatinine
and albumin levels; urinary calcium, phosphorous and creatinine
were estimated by Beckman automated analyzer (CX 9, California,
USA) using commercial kits. The detailedmethodology is described
in our previous publications.11
The normal laboratory range for serum calcium is 8.5–10.5 mg/
dl, serum phosphorous 2.5–4.5 mg/dl and for SAP is <95 IU/l in
adults and 40–390 IU/l in children before epiphyseal closure. From
the calculated values, creatinine clearance (Cr.Cl), calcium creati-
nine ratio (Ca.Cr) and phosphate excretion index (PEI) were
derived. The urinary calcium excretion per kilogram bodyweight
(U.Ca/kg/BW) was calculated. Values less than 2 mg/kg/body-
weight was deﬁned as hypocalciuria.
The 25(OH)D concentrations were measured in duplicate by
competitive radioimmunoassay after acetonitrile extraction (Dia-
Sorin, Stillwater, MN, USA, catalogue no. 68100E). The minimaldetectable limit of 25(OH)D assay is 5.0 ng/ml. N-tact PTH was
measured in duplicate by immunoradiometric assay (IRMA)
(DiaSorin, Stillwater, MN, USA, catalogue no. 26100). The minimal
detectable limit of N-tact PTH assay is 0.7 pg/ml. Vitamin D status
was classiﬁed as vitamin D – deﬁcient, – insufﬁcient and –
sufﬁcient or replete on the basis of 25(OH)D concentrations of
<20 ng/ml [25(OH)D deﬁciency], 20–30 ng/ml [25(OH)D insufﬁ-
ciency] and >30 ng/ml [25(OH)D replete state], respectively.13–15
All subjects recruited and those followed on AED therapy were
classiﬁed based on 25(OH)D levels. Subjects with 25(OH) D levels
less than 20 ng/ml were excluded from the study and were
supplemented with vitamin D (as it is unethical to restrict
supplementation in the background of vitamin D deﬁciency and
AED therapy, for fear of increased risk of fractures in the event of a
seizure). All other subjects on AED were included in the study and
followed up. They were evaluated every month for their seizure
control and any other confounding factors. At the end of 6 months,
themetabolic bone disease proﬁle and serum levels of antiepileptic
drugs (PHT, CBZ, and PB)were evaluated. Therewas no patientwho
declined to participate in the study.
3. Statistical methods
A statistical analysis was performed using SPSS package
(version 11.5, SPSS Inc, Chicago, IL). Descriptive results are
presented as mean  standard error of mean (SEM). Lower and
upper bound conﬁdence intervals (CI) are given in parenthesis. Paired
t-test was conducted to study the group before and after therapy.
Pearson’s rank test was used for the correlation analysis when
necessary. Probability values<0.05 were considered signiﬁcant. One-
way analysis of variance (ANOVA) was used to estimate the
differences between the study groups.
4. Results
A total of 144 subjects were evaluated during the study. The
mean  SEM age of the subjects was 29.3  1.2 years (CI 27–32)
(range 12–65 years). The M:F ratio was 1.5:1. Twelve patients (8.3%)
had status epilepticus and 54 (37.5%) had cluster attacks. As per the
ILAE 38 (26.4%) had localization related symptomatic epilepsy, 20
(13.9%) had localization related cryptogenic epilepsy, 85 (59%) had
generalized Idiopathic epilepsies and one was unclassiﬁed (0.7%).
Computerized tomography of the brain showed the following
features: Gliosis 1; calciﬁed lesion 15; old infarct 5; Neurocysticer-
cosis 16.
The total calories (TC) consumed daily of the whole group was
2036  16 (2006–2066) kcal/day, daily dietary calcium (DC) intake
was 304  4 (297–311) mg/day, daily dietary phosphorous was
647  6.4 (634–660) mg/day and phytate to calcium ratio
0.48  0.02 (0.46–0.51). The total calories and DC consumed by
maleswere signiﬁcantly higher than that of the females 2068  20 vs.
1989  24 kcal/day (P < 0.01) and 311  4.6 vs. 295  5 (P < 0.03),
respectively. There was a positive correlation between the TC and DC
(r = 0.4; P < 0.001); TC and dietary phytates (r = 0.3; P < 0.001) and
DC with dietary phytates (r = 0.6; P < 0.001).
The biochemical indices of bonemineral metabolism are shown
in Table 1. The serum albuminwas in the normal range 3.82  0.03
(gm/dl). 25(OH)D deﬁciency (<20 ng/ml) was seen in 68% (n = 98),
25(OH)D insufﬁciency (20–30 ng/ml) in 22% (n = 32) and 25(OH)D
replete state (greater than 30 ng/ml) in 10% (n = 14) of the study
group. The urinary calcium/kg/bodyweight was signiﬁcantly
(P < 0.05) different among various groups of 25(OH)D deﬁciency
(Table 1) declining with severity of 25(OH)D deﬁciency. Similarly
changes were observed with PEI also (P < 0.001).
N-tact PTH correlated negatively with 25(OH)D (r = 0.18;
P < 0.03) (the relationship between N-tact PTH and 25(OH)D is
Table 1
Table depicting the biochemical and hormonal indices of bone mineral metabolism of the patients at recruitment.
Parameter Whole group (n=144) 25(OH)D <20ng/ml (n=98) 25(OH)D 20–30ng/ml (n=32) 25(OH)D >30ng/ml (n=14)
Mean SEM Mean SEM Mean SEM Mean SEM
S.Ca (mg/dl) 9.78 0.04
(9.70–9.86)
9.8 0.05
(9.7–9.9)
9.77 0.08
(9.61–9.94)
9.760.14
(9.45–10.1)
S.Phos (mg/dl) 3.85 0.1
(3.7–4)
3.75 0.1
(3.57–3.92)
3.95 0.17
(3.6–4.3)
4.30.21*
(3.84–4.75)
SAP (IU/l) 95.245.44
(84.5–106)
94.546.7
(81.27–107.80)
868.52
(68.56–103.37)
120.5023.32
(70.13–171)
TRACP (IU/l) 8.63 0.68
(7.29–9.97)
8.58 0.73
(7.13–10)
7.151.58
(3.92–10.38)
12.173.07
(5.53–18.8)
25(OH)D (ng/ml) 16.9 0.7
(15.4–18.4)
11.9 0.5**
(10.9–12.8)
24.7 0.5**
(23.6–25.8)
35.41**
(33.3–37.6)
N-tact PTH
(pg/ml)
25.12.2
(20.8–29.4)
263
(20.2–31.8)
24.2.7
(18.6–29.5)
216.4
(7.1–34.8)
S.Cr (mg/dl) 0.86 0.03
(0.8–0.93)
0.87 0.04
(0.8–0.95)
0.890.06
(0.8–1.00)
0.770.06
(0.7–0.9)
ALB (gm/dl) 3.82 0.03
(3.76–3.87)
3.81 0.03
(3.74–3.87)
3.81 0.06
(3.69–3.94)
3.910.08
(3.73–4.10)
U.CA (mg/day) 1076
(96–119)
1037
(90–117)
12012
(96–144)
10719
(65–149)
U.PHO 38119
(344–418)
39523
(349–442)
37538
(297–453)
30151
(191–410)
U.Ca/Wt
(mg/day)
2.04 0.11
(1.81–2.26)
1.90 0.13*
(1.64–2.17)
2.28 0.25*
(1.76–2.80)
2.370.35*
(1.61–3.12)
Ca.Cr 0.12 0.01
(0.11–0.14)
0.11 0.01
(0.10–0.13)
0.140.02
(0.11–0.17)
0.150.02
(0.10–0.19)
PEI 0.05 0.01
(0.06 to 0.03)
0.03 0.01*
(0.05 to 0.01)
0.060.01*
(0.09 to 0.03)
0.110.02*
(0.14 to 0.08)
Mean SEM all such values; values in the parenthesis – conﬁdence intervals. 25(OH)D: 25-hydroxyvitamin D; N-tact PTH: intact PTH; S.Ca: serum calcium; S.Phos: serum
phosphorus; SAP: serum alkaline phosphatase; S.Cr: serum creatinine; S.Alb: serum albumin; U.Ca: urinary calcium; U.Ca/Wt: urinary calcium/kg/bodyweight; Ca.Cr: calcium to
creatinine ratio; U.Phos: urinary phosphorous; and PEI: phosphate excretion index.
The main effect of 25(OH)D on age is not signiﬁcant (F =0.057; P =0.94) and on gender is not signiﬁcant (F =0.52; P =0.47). The interactions of age and gender on 25(OH)D is not
signiﬁcant (F =0.023; P =0.98).
* P<0.05.
** P<0.001.
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R2 = 0.9818; P < 0.0001); with serum calcium (r = 0.24; P < 0.01)
and PEI (r = 0.26; P < 0.002). A positive correlation was observed
between serum phosphorous vs. 25(OH)D (r = 0.21; P < 0.01); and
urinary calcium/kg/bodyweight (r = 0.19; P < 0.03). TRACP corre-
lated positively with serum albumin (r = 0.22; P < 0.01) and
negativelywith dietary phytates (r = 0.32; P < 0.001) and phytate
to calcium ratio (r = 0.2; P < 0.03).
{Two years back, at the time of recruitment of patients for the
study previous classiﬁcation of vitamin D status was used. Vitamin
D status was classiﬁed as vitamin D – deﬁcient, – insufﬁcient and –
sufﬁcient or replete on the basis of 25(OH)D concentrations of
<10 ng/ml [25(OH)D deﬁciency], 10–20 ng/ml [25(OH)D insufﬁ-
ciency] and >20 ng/ml [25(OH)D replete state], respectively.}16
Using old classiﬁcation 25(OH)D deﬁciency, 25(OH)D insufﬁciency
and 25(OH)D replete state was seen in 25%, 44%, 31%, respectively.
With the new classiﬁcation13–15 being presently followed (as
deﬁned above), the data was analyzed using the latest cut off.
Thus 46 subjects [25(OH)D replete and insufﬁcient subjects]
qualiﬁed for the longitudinal study. Only 31 subjects reported for
follow-up. They were assessed at the end of 6 months for their
bone mineral parameters along with serum antiepileptic drug
levels. They were also analyzed based on the type and daily dose of
AED used. None of them had clinical signs of drug toxicity. None of
them had clinical history of fracture during 6 months follow-up
period. Six months after therapy serum 25(OH)D levels declined
from 29  1.3 to 17.2  1.6 ng/ml (P < 0.001) (Table 2). Ninety-four
percent of them had either vitamin D deﬁciency or insufﬁciency. Of
them 25(OH)D deﬁciency was found in 65% (n = 20), 25(OH)D
insufﬁciency in 29% (n = 9) and normal 25(OH)D levels in 6% (n = 2)
(Fig. 1a and b). The decline in 25(OH)D levels were observed in all
subjects irrespective of the AED used (Table 3). There was asigniﬁcant fall in urinary calcium (P < 0.001), U.Ca/kg/BW
(P < 0.001). The TRACP levels decreased signiﬁcantly (P < 0.02).
There was no signiﬁcant change in N-tact PTH, SAP and PEI (Table 2).
There was no change in physical activity in these patients during the
course of AED therapy.
5. Discussion
In the present study, all the patients had low dietary calcium
intake compared to Recommended Daily/Dietary Allowance (RDA)
as per ICMR guidelines. Previous studies from south India,
especially, Andhra Pradesh have documented low dietary calcium
intake in the population studied.7,12 This is supported by studies
fromother parts of the country17,18 aswell on immigrant Indians in
USA.19 RDA has been revised and redeﬁned as the Dietary
Reference Intake (DRI).20 The RDA of calcium for Indians
recommended by the Indian Council of Medical Research (ICMR)
is lower than the recently revised DRI.21–23
At recruitment, before initiation of AED therapy 90% of the
subjects had varying degrees of 25(OH)D deﬁciencies. Only 10%
had normal 25(OH)D levels. The linear decline in urinary calcium
in relation to 25(OH)D levels (P < 0.05) document the indirect
evidence of hypovitaminosis D. The normal TRACP levels suggest
that bone resorption was not altered.
Subjects on AED therapy, when evaluated at the end of 6
months showed a signiﬁcant fall of 25(OH)D levels, urinary
calcium, urinary calcium/kg/BW and TRACP levels irrespective of
the type of AED used (Table 2). Earlier studies in children24 and
adults25 have shown decreased urinary excretion of calcium in
patients on PHT, VPA, CBZ. Ninety percent of the subjects studied
longitudinally developed either vitamin D deﬁciency or insufﬁ-
ciency at the end of 6 months of therapy (Fig. 1a and b, Table 3).
Table 2
Table depicting the biochemical and hormonal indices of bone mineral metabolism at recruitment and 6 months after anti epileptic therapy (AED) therapy.
Descriptive Before TRT (n=31) 6 months after TRT (n=31) Paired differences
Mean SEM Mean SEM Mean SEM
S.Ca (mg/dl) 9.640.14 9.78 0.13 0.14 0.11
(9.35–9.94) (9.51–10.05) (0.37 to 0.09)
S.Phos (mg/dl) 4.330.18 40.18 0.27 0.17
(3.97–4.69) (3.68–4.43) (0.08 to 0.63)
SAP (IU/ml) 9412.70 78.209.50 15.8310.35
(68.10–119.97) (58.81–97.60) (5.31 to 36.97)
TRACP (IU/l) 13.432.38 7.200.81 6.232.51*
(7.82–16.86) (5.48–8.58) (1.05–11.40)
25(OH)D (ng/ml) 291.34 17.201.57 11.881.67**
(26.34–31.82) (13.98–20.41) (8.47–15.30)
N-tact PTH (pg/ml) 25.368 28.544.64 3.464.50
(9.17–41.56) (19.06–38.03) (12.66 to 5.74)
U.Ca (mg/day) 11812.42 679.35 5111**
(98.09–154.25) (46.40–84.02) (28.61–73.43)
U.Phos (mg/day) 37745 349.0646.76 28.3950.33
(291.09–480.38) (244.20–433.70) (75.06 to 131.83)
U.Cal/Wt (mg/kg/BW) 2.560.27 1.39 0.15 1.17 0.27**
(1.96–3.05) (1.07–1.71) (0.61–1.73)
Ca.Cr 0.150.02 0.010.08 0.16 0.09
(0.11–0.18) (0.17 to 0.15) (0.03 to 0.34)
PEI 0.090.02 0.060.02 0.02 0.02
(0.12 to 0.05) (0.10 to 0.03) (0.06 to 0.02)
Mean SEM all such values; values in the parenthesis – conﬁdence intervals. 25(OH)D: 25-hydroxyvitamin D; N-tact PTH: intact PTH; S.Ca: serum calcium; S.Phos: serum
phosphorus; SAP: serum alkaline phosphatase; S.Cr: serum creatinine; S.Alb: serum albumin; U.Ca: urinary calcium; Ca.Cr: calcium to creatinine ratio; U.Phos: urinary
phosphorous; and PEI: phosphate excretion index.
The interaction of 25(OH)D levels after AED treatment is signiﬁcant (R2 = 0.787) with (a) type of AED gender (F =3.268; P =0.05); (b) gender age (F =6.953; P =0.022); type of
AED age gender (F =9.411; P =0.01).
The interactions of TRACP after AED treatment is signiﬁcant (R2 = 0.884) with (a) type of AED gender (F =3.987; P =0.04); (b) age gender (F =7.773; P =0.02); (c) type of
AED age gender (F =8.9; P=0.01).
* P<0.05.
** P<0.001.
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with the serum AED levels (Table 3). Even at sub-therapeutic
plasma level of the changes in calcium and bone metabolism were
observed.
Two mechanisms are proposed for vitamin D inactivation by
AEDs – hepatic enzyme induction and pregnane X receptor (PXR)
and SXR activation.26–28 Vitamin D (D2 and D3) are normally taken
up by the liver and transformed into 25(OH)D by themitochondrial
vitamin D hydroxylase CYP27A. The AED binds to the SXR and
activates it. The complex binds to RXR which then interacts with
the vitamin D responsive element for the 24-OHase.27–32 This
enhances the destruction of 25(OH)D and 1,25(OH)2D. The
accelerated clearance will promote all normal physiological
adaptive mechanisms in response to progressive 25(OH)D
insufﬁciency and consequent secondary hyperparathyroidism.
Hypovitaminosis D leads to decreased calcium absorption in the
intestine. Thus in the background of low dietary calcium intake,
hypovitaminosis D induced by AED will have a detrimental effect
on bone mineral metabolism. There are also genetic factors that
may inﬂuence the susceptibility of individuals to the effect of AED
on vitamin D and bone metabolism.
The other mechanisms of AED induced bone loss include direct
impact of the drug on intestinal calcium transport.33 Physiological
concentrations of vitamin D3 are necessary for maintenance of
aromatase activity necessary in osteoblasts.34–36 In the present
group of subjects, enzyme inducing AED (PHT, PB, CBZ) and
enzyme inhibiting AED (VPA) affected the 25(OH)D metabolism
alike at sub-therapeutic doses of AED. This leads us to speculate
that bone mineral metabolism is affected on those with AED atsub-therapeutic plasma concentrations of the drug level. The other
mechanisms postulated include inducers of cytochrome P450
enzyme system (PB, PHT, CBZ),4,37 reduced intestinal calcium
absorption (PHT),33 impaired response to parathyroid hormone
(PB, PHT), secondary hyperparathyroidism,38 poor vitamin K status
(PHT),39 calcitonin deﬁciency,40 hepatic enzyme inhibition
(VPA),41 and by induction of the 25-hydroxyvitamin D-24-
hydroxylase by the steroid hormone xenobiotic receptor.26
Multi-drug therapy is shown to be associated with high risk of
bone mineral metabolism abnormalities than monotherapy.9,42
Low vitamin D status in patients with epilepsy (PWE) has
various management implications. Low serum 25(OH)D concen-
trations are associated with a higher risk for hip fracture.43,44 PWE
have an increased incidence of falls, seizure related injuries and
fractures.45 The falls may be seizure related or non seizure related
injuries. Vitamin D deﬁciency may also lead to proximal muscle
weakness and falls. Yet another study found that the risk of
fracture may be more common in women on long term AED.46 The
spectrum of epilepsy is varied, with some patients having mental
and motor handicap which might require institutionalization. In
such cases, the physical activity and exposure to sunlight is
restricted. AED associated side effects such as drowsiness; ataxia
and tremor may contribute to gait disturbances with consequent
increased risk of falls and fractures. All these factors add to AED
induced alterations in 25(OH)D. Modiﬁcation of life style, good
exercise programme and nutrition supplementation can lead to
healthy bones.47 Calcium and vitamin D supplementation exerts
its beneﬁcial effects by counterbalancing the heightened vitamin D
requirement induced by AEDs. Bone markers like osteocalcin and
Table 3
25(OH)D and PTH levels baseline and after 6 months of therapy on various AED with corresponding serum drug levels and the daily dose of AED used.
Drug 25(OH)D
ng/ml
Baseline
25(OH)D
ng/ml
AFT TRT*
N-tact PTH
pg/ml
Baseline
N-tact PTH
pg/ml
AFT TRT*
Drug level
mg/ml
Drug dose
mg/day
CBZ (n=7) 32.53 18.44.4 14.223 23.32.7 7.604.4 40087
CLB (n=3) 255 14.374.5 16.61.3 37.53.8 – 155
PB (n=2) 211 8.9 0.4 20.17.7 33.23.8 9.70 9030
PHT (n=14) 28.12.2 17.32.3 19.23.6 19.54.3 10.67 25714
VPA (n=3) 31.42.2 21.774.5 9577 6443 – 61773
Poly therapy (n=2) 312 22.33.7 22.34.8 29.58.6 –
Mean SEM all such values; values in the parenthesis – conﬁdence intervals. (Normal serum range of drug levels: CBZ: 4–11mg/ml; PHT: 10–20mg/ml; PB: 15–40mg/ml.).
* P<0.05.
B. Menon, C.V. Harinarayan / Seizure 19 (2010) 153–158 157cross laps would have thrown more light but were limited by
constraints of funds. Bone histomorphometry would have also
helped. Because of ethical considerations it could not be done.
There are certain methodological limitations in the study. A
largernumberofpatients indifferent categories ofdrugsused, closer
follow-up (earlier than 6 months) and a control group would have
added strengthof this study. Thehighprevalence of lowvitaminDat
study entry may just be a mere illustration of the prevalent low
25(OH)D levels in the population. But the most signiﬁcantFig. 1. (a) Individual changes in 25(OH)D and corresponding PTH levels at baseline
and 6 months after AED therapy. (b) The mean and SEM of the 25(OH)D levels and
their corresponding PTH levels at baseline and 6 months after AED therapy. The
categorization into three groups 25(OH)D deﬁciency (Gr-1), sufﬁciency (Gr-2) and
replete state (Gr-3) are based on the 25(OH)D levels at the end of AED therapy.information of the study is that those with normal 25(OH)D levels
irrespective of the type of antiepileptic medications went into
various of 25(OH)D deﬁciency and insufﬁciency states at sub-
therapeutic levels of the drug in a period of 6 months. However, the
available data leads us to speculate that the diet in person with
epilepsy need to be supplemented with calcium and vitamin D at
initiation of AED therapy in Indiawhere there is lowdietary calcium
intake and wide spread vitamin D deﬁciency.48 There are yet no
consensusguidelines as towhether abaseline screening for thebone
mineral indices is essential. Our study shows that if the patients had
not been screened for their bone health, we would have missed the
majority of patients with low 25(OH)D levels and would have
continued onAEDwhichwould prove detrimental. A dropout rate of
30% (n = 15) in our study could be due to their low socioeconomic
status. This also highlights the treatment gap in epilepsy in India
which could be due to economic, social and cultural reasons. Any
changes inbonemineral density (BMD)measurements are observed
only after 18 months of therapy. Hence biochemical and hormonal
parameter evaluation is very important.
To the best of our knowledge, this is the ﬁrst study to document
the changes in bone mineral parameters at baseline and on follow-
upwith AED therapy along with the plasma AED levels in India. The
accumulated evidence shows that there is a need for more bone
health awareness and counseling of patients regarding calcium and
vitaminD intake, sunlight exposureandphysical activity.Goodbone
health practices should be a part of discussion with the patient
before initiationofAED. Furthermulticentreprospective studies and
guidelines are needed for treating bone metabolism in epilepsy.
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